www.youtube.com/watch?v=zxx_e-DSdak

Link:
IndiaMART Leaders of Tomorrow AWards 2011 – Regenerative Medical Services Pvt Ltd – Video

Follow this link:
Tengion to Present at the 14th Annual BIO CEO & Investor Conference

Continue reading here:
IntelliCell Demonstrates at the American Sports Medicine Institute Held in Conjunction with and at the Andrews Sports …

(SACRAMENTO, Calif.) – Experts from UC Davis Health System will share the latest research about regenerative medicine, with a focus on chronic pain and the promise of stem cell therapies, during a community forum on the university's Sacramento campus. The discussion takes place on Tuesday, Feb. 7, from 6- 7:30 p.m. at the UC Davis Education Building, 4610 X Street, in Sacramento.

The event features Jan Nolta, director of the UC Davis Institute for Regenerative Cures; Scott Fishman, chief of the UC Davis Division of Pain Medicine; and Kee Kim, chief of spinal neurosurgery at UC Davis Medical Center. The three specialists will discuss the challenges of treating chronic pain, especially back and neck pain, and the clinical research now under way to use stem cell therapies to overcome it.

The forum is free and open to the public. It is part of “Stem Cell Dialogues,” UC Davis Health System's discussion series about regenerative medicine and the goal of turning stem cells into cures. Each speaker will provide a short presentation followed by a panel discussion and question and answer period. The event will be moderated by Fred Meyers, professor of medicine and pathology, and executive associate dean of UC Davis School of Medicine.

Seating is limited. Those interested in attending must reserve a seat by contacting Kate Rodrigues at 916-734-9404 or e-mail kathleen.rodrigues@ucdmc.ucdavis.edu. Doors open at 5:30 p.m.  Free parking will be available in Lots 12 and 14, just south of the Education Building, near 45th Street and 2nd Avenue.

UC Davis is playing a leading role in regenerative medicine, with nearly 150 scientists working on a variety of stem cell-related research projects at campus locations in both Davis and Sacramento. The UC Davis Institute for Regenerative Cures, a facility supported by the California Institute for Regenerative Medicine (CIRM), opened in 2010 on the Sacramento campus. This $62 million facility is the university's hub for stem cell science. It includes Northern California's largest academic Good Manufacturing Practice laboratory, with state-of-the-art equipment and manufacturing rooms for cellular and gene therapies. UC Davis also has a Translational Human Embryonic Stem Cell Shared Research Facility in Davis and a collaborative partnership with the Institute for Pediatric Regenerative Medicine at Shriners Hospital for Children Northern California. All of the programs and facilities complement the university's Clinical and Translational Science Center, and focus on turning stem cells into cures. For more information, visit www.ucdmc.ucdavis.edu/stemcellresearch.

Read more from the original source:
The promise of stem cell therapies forum

WALTHAM, Mass.–(BUSINESS WIRE)–

Histogenics Corporation, a privately held, regenerative medicine company, today announced that President and Chief Executive Officer Patrick O’Donnell will present at the upcoming Canaccord Genuity Musculoskeletal Conference on February 7th at 3:30pm PT at the Parc 55 Wyndham in San Francisco. Mr. O’Donnell will discuss the Company’s lead product candidates, including NeoCart®, an autologous bioengineered neocartilage grown outside the body using the patient’s own cells for the regeneration of cartilage lesions and VeriCart™, a three-dimensional cartilage matrix to stimulate cartilage repair in a simple, one-step procedure. NeoCart recently entered a Phase 3 clinical trial and will be the subject of an oral presentation at the Annual Meeting of the American Academy of Orthopaedic Surgeons (AAOS), which is also taking place in San Francisco from February 7th-11th.

About Histogenics

Histogenics is a leading regenerative medicine company that combines cell therapy and tissue engineering technologies to develop highly innovative products for tissue repair and regeneration. In May of 2011, Histogenics acquired Israeli cell-therapy company Prochon BioTech. Histogenics’ flagship products focus on the treatment of active patients suffering from articular cartilage derived pain and immobility. The Company takes an interdisciplinary approach to engineering neocartilage that looks, acts and lasts like hyaline cartilage. It is developing new treatments for sports injuries and other orthopaedic conditions, where demand is growing for long-term alternatives to joint replacement. Histogenics has successfully completed Phase 1 and Phase 2 clinical trials of its NeoCart autologous tissue implant and is currently in a Phase 3 IND clinical study. Based in Waltham, Massachusetts, the company is privately held. For more information, visit www.histogenics.com.

Read the original:
Histogenics Corporation to Present at Canaccord Genuity Musculoskeletal Conference

Here is the original post:
Kensey Nash Reports Second Quarter Fiscal Year 2012 Financial Results

www.youtube.com/watch?v=HMAbzHj2g9M

Link:
Dr Aziz Denian Transcranial Magnetic Stimulation 2011 ForVideoRecordShrinked2 pptx – Video

www.youtube.com/watch?v=Bsc3newjNVc

Excerpt from:
2011 Summit: Keynote Address, CIRM’s Translational Roadmap to Stem Cell Cures, Alan Trounson, PhD – Video

Speakers include Advanced Cell Technology, Athersys, Cytori, Dendreon,

Genzyme-Sanofi, Johnson & Johnson, Mesoblast and Shire

WASHINGTON, DC, January 5, 2012 – The Alliance for Regenerative Medicine (ARM), the international organization representing the interests of the regenerative medicine (RM) community, today released the agenda for its second annual State of the Industry Briefing and RM Insight Track. The meeting will take place on January 10 – 11, 2012 at the Park 55 Wyndham in San Francisco.

The Regenerative Medicine State of the Industry Briefing will focus on recent developments and the future outlook for regenerative medicine, cell therapy and other advanced therapeutics. A full day of panels focused on several disease areas will follow the briefing as part of the Regenerative Medicine Insight track at the Biotech Showcase 2012. The panels will be moderated by key analysts in the sector. Please see agenda below:

Tuesday, January 10, 2012

8:00 – 9:30 AM Regenerative Medicine State of the Industry Briefing

Gil Van Bokkelen, CEO, Athersys (Moderator) Silviu Itescu, CEO, Mesoblast Tim Mayleben, CEO of Aaastrom Gary Rabin, CEO, Advanced Cell Technology Robin Smith, CEO, NeoStem Leanna Caron, VP & GM of Cell Therapy & Regenerative Medicine, Genzyme-Sanofi Ed Field, COO, Aldagen Jay Seigal, CBO, Johnson & Johnson Dean Tozer, Senior VP of Corporate Development, ABH-Shire Susan Solomon, CEO, New York Stem Cell Foundation

Therapeutic Focus Panels

9:30 – 10:45 AM Cardiovascular, AMI and PAD—Part 1

Analyst: Jason Butler, JMP Securities

Amorcyte, Andrew Pecora, CSO Cytori, Marc Hendrick, President Athersys, Gil Van Bokkelen, CEO Mesoblast, Silviu Itescu, CEO

10:50AM – 12:15 PM Cardiovascular, CLI and Stroke—Part 2

Analyst: Ren Benjamin, Rodman and Renshaw

Aastrom, Brian Gibson, VP Finance ReNeuron, Michael Hunt, CEO Aldagen, Ed Field, COO Tissue Genesis, Anton Krucky, CEO SanBio, Keita Mori, CEO

1:45 – 3:00 PM Neurodegenerative Disease, Ophthalmology and Spinal Injury

Analyst: Steve Brozak, WBB Securities

StemCells, Inc., Martin McGlynn, CEO NeuralStem, Richard Garr, CEO InVivo, Frank Reynolds, Chairman of the Board, CEO, CFO, Advanced Cell Technology, Gary Rabin, CEO

3:00 – 4:15 PM Renal and AutoImmune Disease

Analyst: Kai Makay, Roth Capital

Tengion, Mark Stejbach, VP, CCO Allocure, John Wirthlin, COO Tigenix, Eduardo Bravo, CEO Q Therapeutics, Deborah Eppstein, CEO

4:20 – 5:45 PM Tissue Engineering, Orthobiologics and Artificial Conduits to Wound Care and BioPrinting

Analyst: Jeffery Cohen, Ladenburg Thalmann & Co.

ISTO, Scott Gill, CFO Organovo, Keith Murphy, CEO ABH – Shire, Dean Tozer, Senior VP of Corporate Development Healthpoint, Rob Bancroft, VP, Strategic and Corporate Development Axogen, Karen Zaderej, CEO · Harvard Biosciences, David Green, CEO

Wednesday, January 11, 2012

9:00 – 10:30 AM Hematology & Immunology

Analyst: Stephen Dunn, LifeTech Capital

Dendreon, David L. Urdal, Executive VP, CSO Prima BioMed, Martin Rogers, CEO ImmunoCellular, Manish Singh, CEO Coronado, Bobby Sandage, CEO bluebird bio, Jeffrey Walsh, COO NexImmune, Ken Carter, CEO Maxcyte, Doug Doerfler, CEO

To learn more and to register for the conference, please contact Rob Margolin at (646) 201-4192. Registration is complimentary for credentialed members of the media and the investment community. The State of the Industry briefing is open to the public, but attendance at the disease panels will require registration for individuals without press or investor credentials.

About Biotech Showcase™ (Innovation – Opportunity – Collaboration):

Now in its fourth year, Biotech Showcase™ will feature corporate presentations by 200+ innovative life science companies to an audience of public and private investors, business development executives and professional advisors who are interested in investment opportunities and collaboration. The showcase takes place during the week of the annual JP Morgan Healthcare Conference, one of the most important healthcare industry events of the year which attracts thousands of healthcare and life science business executives to San Francisco. Biotech Showcase was co-founded by Demy-Colton Life Science Advisors and EBD Group. Please visit their website for more information: www.biotechshowcase.com.

About The Alliance for Regenerative Medicine (ARM)

ARM is a Washington, DC-based non-profit organization that promotes legislative, regulatory, reimbursement, and financing initiatives necessary to facilitate access to life-giving advances in regenerative medicine. ARM also works to increase public understanding of the field and its potential to transform human healthcare, and provides services to support the growth of its member companies and organizations. Prior to the formation of ARM in September 2009, there was no advocacy organization operating in Washington, DC to specifically represent the interests of regenerative medicine companies, research institutions, investors, and patient groups supporting more rapid adoption of technologies in our field. To learn more about ARM or to become a member, visit www.alliancerm.org.

Distributed by www.proactivenewsrom.com

ProActive Capital Resources Group LLC.

View original post here:
Coronado Biosciences to attend the Alliance for Regenerative Medicine Biotech conference in San Francisco

www.youtube.com/watch?v=VsRhKZitpqQ

Read the original:
Mark Walter, MD introduces Prolotherapy and PRP: The New Field of Regenerative Medicine – Video

Halfway through its initial ten-year mandate, the California Institute for Regenerative Medicine (CIRM) in San Francisco is confronting a topic familiar to anyone at middle age: its own mortality.

The publicly funded institute, one of the world’s largest supporters of stem-cell research, was born from a state referendum in 2004. Endorsements from celebrities such as then-state governor Arnold Schwarzenegger and the late actor Christopher Reeve, who had been paralysed by a spinal injury, helped to garner voter support for a public bond to underwrite the institute. But with half of the US$3 billion that it received from the state now spent and the rest expected to run out by 2021, CIRM is now actively planning for a future that may not include any further state support.

“It would be premature to even consider another bond measure at this time,” wrote Jonathan Thomas, CIRM’s chairman, in a draft of a transition plan requested by the state legislature. Thomas outlined the plan on 24 January at a public hearing held in San Francisco by the US Institute of Medicine, which CIRM has asked to review its operations.

Given that California is facing severe budget shortfalls, several billion dollars more for stem-cell science may strike residents as a luxury that they can ill afford. It may also prove difficult for CIRM’s supporters to point to any treatments that have emerged from the state’s investment. So far, the agency has funded only one clinical trial using embryonic stem cells, and that was halted by its sponsor, Geron of Menlo Park, California, last November.

Yet the institute has spent just over $1 billion on new buildings and labs, basic research, training and translational research, often for projects that scientists say are crucial and would be difficult to get funded any other way. So the prospect of a future without CIRM is provoking unease. “It would be a very different landscape if CIRM were not around,” says Howard Chang, a dermatologist and genome scientist at Stanford University in California.

“It would be a very different landscape if CIRM were not around.”

Chang has a CIRM grant to examine epigenetics in human embryonic stem cells, and is part of another CIRM-funded team that is preparing a developmental regulatory protein for use as a regenerative therapy. Both projects would be difficult to continue without the agency, he says. Federal funding for research using human embryonic stem cells remains controversial, and could dry up altogether after the next presidential election (see Nature 481, 421–423; 2012). And neither of Chang’s other funders — the US National Institutes of Health (NIH) and the Howard Hughes Medical Institute in Chevy Chase, Maryland — supports his interdisciplinary translational work. Irina Conboy, a stem-cell engineer at the University of California, Berkeley, who draws half of her lab’s funding from CIRM, agrees that in supporting work that has specific clinical goals, the agency occupies a niche that will not easily be filled by basic-research funders. “The NIH might say that the work does not have a strong theoretical component, so you’re not learning anything new,” she says.

CIRM is developing plans to help its grantees to continue their work if the agency closes. One option is a non-profit ‘venture philanthropy’ fund that would raise money from private sources to support stem-cell research. The agency is also writing a strat­egic plan for the rest of its ten-year mandate that focuses on translating research into the clinic, acknowledging that CIRM’s best shot at survival — and at sustaining future funding for stem-cell researchers — could come from a clinical success.

As CIRM board member Claire Pomeroy, chief executive of the University of California, Davis, Health System in Sacramento, noted at the agency’s board meeting on 17 January: “If you asked the public what they would define as success, they would say a patient benefited.”

See the rest here:
Stem-cell agency faces budget dilemma

Go here to see the original:
ACT Announces Aberdeen Royal Infirmary in Scotland as Additional Site for Phase 1/2 Clinical Trial Using hESC-Derived …

Read more:
Regenerative medicine company encouraged by heart failure trial

Go here to see the original:
ACT Announces that Additional Patient with Stargardt’s Disease Has Undergone Embryonic Stem Cell Transplantation at …

www.youtube.com/watch?v=5vI9otTJhCM

Read the original:
Bio-Dundee Conference 2011 – Regenerative Medicine – Video

Read the original here:
ACT Publishes First Report of Embryonic Stem Cell (ESC)-Derived Cells Transplanted Into Patients

Read the original post:
Regenerative medicine firm KeraNetics closes in on $7M in financing

Excerpt from:
Regenerative medicine firm TAPs Cambridge expertise

www.youtube.com/watch?v=WR4qZ1EO0nI

More:
Center for Preventative and Regenerative Medicine – Video

Read the original here:
Regenerative medicine for lung disease focus of $2.5 million Penn grant